EARNEST Partners
MYGN icon

EARNEST Partners’s Myriad Genetics MYGN Stock Holding History

EARNEST Partners’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,977,292
Closed -$35.3M – 294
2025
Q1 		$35.3M Buy
3,977,292
+5,694
+0.1% +$68.4K 0.17% 158
2024
Q4 		$54.5M Buy
3,971,598
+15,650
+0.4% +$289K 0.24% 140
2024
Q3 		$108M Sell
3,955,948
-116,070
-3% -$3.14M 0.47% 84
2024
Q2 		$99.6M Buy
4,072,018
+138,960
+4% +$3.05M 0.47% 87
2024
Q1 		$83.9M Buy
3,933,058
+19,145
+0.5% +$412K 0.38% 101
2023
Q4 		$74.9M Buy
3,913,913
+440,632
+13% +$7.62M 0.37% 109
2023
Q3 		$55.7M Buy
3,473,281
+219,503
+7% +$4.18M 0.32% 121
2023
Q2 		$75.4M Buy
3,253,778
+192,940
+6% +$4.21M 0.42% 103
2023
Q1 		$71.1M Sell
3,060,838
-243,618
-7% -$4.95M 0.41% 103
2022
Q4 		$47.9M Sell
3,304,456
-3,265,946
-50% -$60.9M 0.29% 124
2022
Q3 		$125M Buy
6,570,402
+108,264
+2% +$2.48M 0.84% 34
2022
Q2 		$117M Buy
6,462,138
+185,078
+3% +$3.84M 0.78% 42
2022
Q1 		$158M Sell
6,277,060
-39,305
-0.6% -$1.01M 0.94% 27
2021
Q4 		$174M Buy
6,316,365
+64,554
+1% +$1.87M 1.01% 28
2021
Q3 		$202M Buy
6,251,811
+58,332
+0.9% +$1.94M 1.23% 17
2021
Q2 		$189M Sell
6,193,479
-991,871
-14% -$28.7M 1.11% 24
2021
Q1 		$219M Buy
7,185,350
+453,921
+7% +$12.9M 1.31% 14
2020
Q4 		$133M Buy
6,731,429
+1,785,819
+36% +$28.8M 0.92% 35
2020
Q3 		$64.5M Buy
4,945,610
+184,528
+4% +$2.34M 0.56% 76
2020
Q2 		$54M Buy
4,761,082
+600,798
+14% +$8.53M 0.51% 86
2020
Q1 		$59.5M Buy
4,160,284
+561,534
+16% +$11.9M 0.67% 58
2019
Q4 		$98M Buy
3,598,750
+210,501
+6% +$5.79M 0.77% 51
2019
Q3 		$97M Buy
+3,388,249
New +$98.7M 0.88% 39

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GCM
Glenview Capital Management New York $3.98B AUM 20.52% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

EARNEST Partners's MYGN Position: Q2 2025 in Review

EARNEST Partners sold out of Myriad Genetics (MYGN) in Q2 2025, closing a stake of 3,977,292 shares — an estimated $35.3M sold.

EARNEST Partners first reported a position in MYGN in Q3 2019 and held it in 23 quarters. The position peaked at $219M in Q1 2021. 221 funds tracked by Wall St. Rank hold MYGN as of Q2 2025.

  • EARNEST Partners reported no remaining Myriad Genetics position as of Q2 2025 after selling out during the quarter.
  • EARNEST Partners sold 3,977,292 Myriad Genetics shares in Q2 2025, an estimated $35.3M.
  • EARNEST Partners first reported a position in Myriad Genetics in Q3 2019 and held it in 23 quarters.
  • EARNEST Partners's Myriad Genetics position peaked at $219M in Q1 2021.
  • 221 funds tracked by Wall St. Rank held Myriad Genetics as of Q2 2025.

Based on EARNEST Partners's 13F filing for Q2 2025, filed 15 Aug 2025.